Summary
Cencora, Inc. (COR) has filed an 8-K to disclose an update to its fiscal year 2025 financial guidance, which will be presented at the Leerink Partners Global Healthcare Conference on March 10, 2025. The company has raised its adjusted diluted earnings per share (EPS) forecast for FY2025 to a range of $15.30 to $15.60, an increase from the prior guidance of $15.25 to $15.55. This upward revision is attributed to continued positive momentum in the Company's core U.S. Healthcare Solutions segment during the second quarter of fiscal 2025. Importantly, this updated guidance does not incorporate any changes or expectations related to the recently completed acquisition of Retina Consultants of America, suggesting that potential impacts from this acquisition have not yet been factored into the revised EPS outlook. Investors should note that the provided EPS is a non-GAAP measure, and the company details specific exclusions used in its calculation, such as gains from antitrust litigation, amortization of acquisition-related intangibles, and other one-time or non-recurring items. Cencora emphasizes that this non-GAAP measure is used by management for operational evaluation and performance assessment.
Key Highlights
- 1Cencora, Inc. (COR) announced an increase in its fiscal year 2025 adjusted diluted EPS guidance.
- 2The new FY2025 adjusted diluted EPS forecast is $15.30 - $15.60, up from the previous $15.25 - $15.55 range.
- 3The guidance update reflects strong performance and continued momentum in the U.S. Healthcare Solutions segment during Q2 FY2025.
- 4The updated guidance does NOT include any impact from the recently completed acquisition of Retina Consultants of America.
- 5Cencora will be presenting this information at the Leerink Partners Global Healthcare Conference on March 10, 2025.
- 6The disclosed EPS figure is a non-GAAP measure, excluding various one-time and non-recurring items.
- 7The company provides a detailed list of adjustments made to calculate adjusted diluted EPS.